Cidara Therapeutics Stock Today
| CDTX Stock | USD 23.10 0.35 1.54% |
PerformanceWeak
| Odds Of DistressLow
|
Cidara Therapeutics is trading at 23.10 as of the 20th of March 2025; that is 1.54 percent increase since the beginning of the trading day. The stock's open price was 22.75. Cidara Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of April 2015 | Category Healthcare | Classification Health Care |
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. Cidara Therapeutics, Inc. The company has 10.95 M outstanding shares of which 181.99 K shares are currently shorted by private and institutional investors with about 2.38 trading days to cover. More on Cidara Therapeutics
Moving against Cidara Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Cidara Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Jeffrey Stein | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCidara Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cidara Therapeutics' financial leverage. It provides some insight into what part of Cidara Therapeutics' total assets is financed by creditors.
| |||||
Cidara Therapeutics (CDTX) is traded on NASDAQ Exchange in USA. It is located in 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121 and employs 38 people. Cidara Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 249.19 M. Cidara Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.95 M outstanding shares of which 181.99 K shares are currently shorted by private and institutional investors with about 2.38 trading days to cover.
Cidara Therapeutics currently holds about 53.08 M in cash with (176.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74.
Check Cidara Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cidara Therapeutics is $249.19 Million. Over half of Cidara Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cidara Ownership Details
Cidara Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2024-12-31 | 55.5 K | |
| Longwood Capital Partners Llc | 2024-12-31 | 54.5 K | |
| Ikarian Capital, Llc | 2024-12-31 | 53.9 K | |
| Geode Capital Management, Llc | 2024-12-31 | 53.1 K | |
| Schonfeld Strategic Advisors Llc | 2024-12-31 | 49.6 K | |
| Stempoint Capital Lp | 2024-12-31 | 47.6 K | |
| Ubs Group Ag | 2024-12-31 | 46.9 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 42.6 K | |
| Millennium Management Llc | 2024-12-31 | 36 K | |
| Bvf Inc | 2024-12-31 | 1.1 M | |
| Ra Capital Management, Llc | 2024-12-31 | 1.1 M |
Cidara Therapeutics Historical Income Statement
Cidara Stock Against Markets
Cidara Therapeutics Corporate Management
| Carol Waldo | VP Assurance | Profile | |
| Preetam MBA | Principal Officer | Profile | |
| James Balkovec | VP Research | Profile | |
| Taylor Sandison | Acting Chief Medical Officer | Profile | |
| SPHR CCP | Senior Culture | Profile | |
| Jim MBA | Chief Officer | Profile |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.